secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001753926-25-000585
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright
---------------------------------------------------------------------

- ATM agreement for up to $2,641,881 of common stock at market prices.
- H.C. Wainwright receives 3.0% cash commission on gross proceeds.
- Proceeds will be used for working capital and general corporate purposes.
- Shares offered under existing effective S-3 shelf registration.
- No obligation to sell; company may suspend or terminate at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000585/0001753926-25-000585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000585/g084763_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer